WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announces that new data from its investigational immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting & Associated Programs, November 4–8, 2015 at the Gaylord National Resort & Convention Center in National Harbor, MD. Safety and efficacy data from a Phase 1/2 study evaluating epacadostat, Incyte’s selective IDO1 inhibitor, in combination with pembrolizumab, an anti-PD-1 therapy, will be presented as a late-breaking oral presentation. Additionally, data from INCB50465, Incyte’s selective PI3Kd inhibitor, will be presented as a poster.
Help employers find you! Check out all the jobs and post your resume.
